Membrane vesicle ABC transporter assays for drug safety assessment

Current Protocols in Toxicology

Volumn 1, Issue SUPPL.54, 2012, Pages

  Van Staden, Carlo J ^a   Morgan, Ryan E ^a   Ramachandran, Bharath ^a   Chen, Yuan ^a   Lee, Paul H ^a   Hamadeh, Hisham K ^a  

^a AMGEN INC   (United States)

Author keywords

ATP binding cassette transporter; Bile salt export pump; Cholestasis; Drug induced liver injury; Multidrug resistance associated protein

Indexed keywords

ABC TRANSPORTER; ADENOSINE TRIPHOSPHATE; BILE SALT; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 3; MULTIDRUG RESISTANCE PROTEIN 4;

ARTICLE; CELL MEMBRANE; CLINICAL PROTOCOL; CURVE FITTING; HIGH THROUGHPUT SCREENING; HUMAN; IC 50; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; LIVER CELL DAMAGE; MEMBRANE FILTER; MEMBRANE VESICLE; PRIORITY JOURNAL; PROTEIN FUNCTION; RISK ASSESSMENT; TOXIC HEPATITIS; BIOASSAY; DRUG EFFECT; DRUG SCREENING; METABOLISM; METHODOLOGY; PHYSIOLOGY; SCINTILLATION COUNTING; STATISTICAL MODEL; TRANSPORT VESICLE;

ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL ASSAY; CELL MEMBRANE; DRUG EVALUATION, PRECLINICAL; HEPATOCYTES; LINEAR MODELS; SCINTILLATION COUNTING; TRANSPORT VESICLES;

EID: 84876025128     PISSN: 19349254     EISSN: 19349262     Source Type: Journal    
DOI: 10.1002/0471140856.tx2305s54     Document Type: Article

References (60)

1. Alrefai, W.A. and Gill, R.K. 2007. Bile acid transporters: Structure, function, regulation and pathophysiological implications. Pharm. Res. 24:1803-1823.
2. Amacher, D.E. 2012. The primary role of hepatic metabolism in idiosyncratic drug-induced liver injury. Expert Opin. Drug Metab. Toxicol. 8:335-347.
3. Belinsky, M.G., Dawson, P.A., Shchaveleva, I., Bain, L.J.,Wang, R., Ling, V., Chen, Z.S., Grinberg, A.,Westphal, H., Klein-Szanto, A., Lerro, A., and Kruh, G.D. 2005. Analysis of the in vivo functions of Mrp3. Mol. Pharmacol. 68:160-168.
4. Benet, L.Z., Broccatelli, F., and Oprea, T.I. 2011. BDDCS applied to over 900 drugs. AAPS J. 13:519-547.
5. Borst, P., de Wolf, C., and van de Wetering, K. 2007. Multidrug resistance-associated proteins 3, 4, and 5. Pflugers Arch. 453:661-673.
6. Dawson, P.A., Lan, T., and Rao, A. 2009. Bile acid transporters. J. Lipid Res. 50:2340-2357.
7. Dawson, S., Stahl, S., Paul, N., Barber, J., and Kenna, J.G. 2012. In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans. Drug Metab. Dispos. 40:130-138.
8. Fattinger, K., Funk, C., Pantze, M., Weber, C., Reichen, J., Stieger, B., and Meier, P.J. 2001. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: A potential mechanism for hepatic adverse reactions. Clin. Pharmacol. Ther. 69:223-231.
9. Feng, B., Xu, J.J., Bi, Y.A., Mireles, R., Davidson, R., Duignan, D.B., Campbell, S., Kostrubsky, V.E., Dunn, M.C., Smith, A.R., and Wang, H.F. 2009. Role of hepatic transporters in the disposition and hepatotoxicity of a HER2 tyrosine kinase inhibitor CP-724,714. Toxicol. Sci. 108:492-500.
10. Fomenko, I., Durst, M., and Balaban, D. 2006. Robust regression for high throughput drug screening. Comput. Methods Programs Biomed. 82:31-37.
11. Fouassier, L., Kinnman, N., Lefevre, G., Lasnier, E., Rey, C., Poupon, R., Elferink, R.P., and Housset, C. 2002. Contribution of mrp2 in alterations of canalicular bile formation by the endothelin antagonist bosentan. J. Hepatol. 37:184-191.
12. Funk, C., Ponelle, C., Scheuermann, G., and Pantze, M. 2001. Cholestatic potential of troglitazone as a possible factor contributing to troglitazoneinduced hepatotoxicity: In vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat. Mol. Pharmacol. 59:627-635.
13. Gradhand, U., Lang, T., Schaeffeler, E., Glaeser, H., Tegude, H., Klein, K., Fritz, P., Jedlitschky, G., Kroemer, H.K., Bachmakov, I., Anwald, B., Kerb, R., Zanger, U.M., Eichelbaum, M., Schwab, M., and Fromm, M.F. 2008. Variability in human hepaticMRP4expression: Influence of cholestasis and genotype. Pharmacogenomics J. 8:42-52.
14. Hamadeh, H.K., Todd, M., Healy, L., Meyer, J.T., Kwok, A.M., Higgins, M., and Afshari, C.A. 2010. Application of genomics for identification of systemic toxicity triggers associated with VEGF-R inhibitors. Chem. Res. Toxicol. 23:1025-1033.
15. Heredi-Szabo, K., Kis, E., Molnar, E., Gyorfi, A., and Krajcsi, P. 2008. Characterization of 5(6)-carboxy-2,7-dichlorofluorescein transport by MRP2 and utilization of this substrate as a fluorescent surrogate for LTC4. J. Biomol. Screen. 13:295-301.
16. Heredi-Szabo, K., Glavinas, H., Kis, E., Mehn, D., Bathori, G., Veres, Z., Kobori, L., von Richter, O., Jemnitz, K., and Krajcsi, P. 2009. Multidrug resistance protein 2-mediated estradiol-17beta-D-glucuronide transport potentiation: in vitroin vivo correlation and species specificity. Drug Metab. Dispos 37:794-801.
17. Hofmann, A.F. 2007. Biliary secretion and excretion in health and disease: current concepts. Ann. Hepatol. 6:15-27.
18. Horikawa, M., Kato, Y., Tyson, C.A., and Sugiyama, Y. 2003. Potential cholestatic activity of various therapeutic agents assessed by bile canalicular membrane vesicles isolated from rats and humans. Drug Metab. Pharmacokinet. 18:16-22.
19. Keppler, D. 2011. Cholestasis and the role of basolateral efflux pumps. Z. Gastroenterol. 49:1553-1557.
20. Kis, E., Ioja, E., Nagy, T., Szente, L., Heredi-Szabo, K., and Krajcsi, P. 2009. Effect of membrane cholesterol on BSEP/Bsep activity: Species specificity studies for substrates and inhibitors. Drug Metab. Dispos. 37:1878-1886.
21. Kis, E., Ioja, E., Rajnai, Z., Jani, M., Mehn, D., Heredi-Szabo, K., and Krajcsi, P. 2011. BSEP inhibition-In vitro screens to assess cholestatic potential of drugs. Toxicol. In Vitro epub ahead of print: http://dx.doi.org/10.1016/j.tiv.2011.11.002.
22. Klaassen, C.D. and Aleksunes, L.M. 2010. Xenobiotic, bile acid, and cholesterol transporters: Function and regulation. Pharmacol. Rev. 62:1-96.
23. Konig, J. 2011. Uptake transporters of the human OATP family: Molecular characteristics, substrates, their role in drug-drug interactions, and functional consequences of polymorphisms. Handbook Exp. Pharmacol. 201:1-28.
24. Kostrubsky, V.E., Strom, S.C., Hanson, J., Urda, E., Rose, K., Burliegh, J., Zocharski, P., Cai, H., Sinclair, J.F., and Sahi, J. 2003. Evaluation of hepatotoxic potential of drugs by inhibition of bile-acid transport in cultured primary human hepatocytes and intact rats. Toxicol. Sci. 76:220-228.
25. Kostrubsky, S.E., Strom, S.C., Kalgutkar, A.S., Kulkarni, S., Atherton, J., Mireles, R., Feng, B., Kubik, R., Hanson, J.,Urda, E., and Mutlib, A.E. 2006. Inhibition of hepatobiliary transport as a predictive method for clinical hepatotoxicity of nefazodone. Toxicol. Sci. 90:451-459.
26. Lee, K.S.,Oh, S.J.,Kim, H.M., Lee, K.H., and Kim, S.K. 2011. Assessment of reactive metabolites in drug-induced liver injury. Arch. Pharm. Res. 34:1879-1886.
27. Leslie, E.M., Watkins, P.B., Kim, R.B., and Brouwer, K.L. 2007. Differential inhibition of rat and human Na+-dependent taurocholate cotransporting polypeptide (NTCP/SLC10A1) by bosentan: A mechanism for species differences in hepatotoxicity. J. Pharmacol. Exp. Ther. 321:1170-1178.
28. Masubuchi, Y. 2006. Metabolic and non-metabolic factors determining troglitazone hepatotoxicity: A review. Drug Metab. Pharmacokinet. 21:347-356.
29. McRae, M.P., Lowe, C.M., Tian, X., Bourdet, D.L., Ho, R.H., Leake, B.F., Kim, R.B., Brouwer, K.L., and Kashuba, A.D. 2006. Ritonavir, saquinavir, and efavirenz, but not nevirapine, inhibit bile acid transport in human and rat hepatocytes. J. Pharmacol. Exp. Ther. 318:1068-1075.
30. Mita, S., Suzuki, H., Akita, H., Stieger, B., Meier, P.J., Hofmann, A.F., and Sugiyama, Y. 2005. Vectorial transport of bile salts across MDCK cells expressing both rat Na+-taurocholate cotransporting polypeptide and rat bile salt export pump. Am. J. Physiol. 288:G159-G167.
31. Morgan, R.E., Trauner, M., van Staden, C.J., Lee, P.H., Ramachandran, B., Eschenberg, M., Afshari, C.A., Qualls, C.W., Jr. Lightfoot-Dunn, R., and Hamadeh, H.K. 2010. Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol. Sci. 118:485-500.
32. Motulsky, H.J. and Brown, R.E. 2006. Detecting outliers when fitting data with nonlinear regression -a new method based on robust nonlinear regression and the false discovery rate. BMC Bioinformatics 7:123.
33. Nadanaciva, S. andWill, Y. 2009. Current concepts in drug-induced mitochondrial toxicity. Curr. Protoc. Toxicol. 40:2.15.1-2.15.9.
34. Nies, A.T. and Keppler, D. 2007. The apical conjugate efflux pump ABCC2 (MRP2). Pflugers Arch. 453:643-659.
35. Noe, J., Stieger, B., and Meier, P.J. 2002. Functional expression of the canalicular bile salt export pump of human liver. Gastroenterology 123:1659-1666.
36. Padda, M.S., Sanchez, M., Akhtar, A.J., and Boyer, J.L. 2011. Drug-induced cholestasis. Hepatology 53:1377-1387.
37. Palmeira, C.M. and Rolo, A.P. 2004. Mitochondrially-mediated toxicity of bile acids. Toxicology 203:1-15.
38. Pauli-Magnus, C. and Meier, P.J. 2005. Hepatocellular transporters and cholestasis. J. Clin. Gastroenterol. 39:S103-S110.
39. Pauli-Magnus, C. and Meier, P.J. 2006. Hepatobiliary transporters and drug-induced cholestasis. Hepatology 44:778-787.
40. Pedersen, J.M., Matsson, P., Bergstrom, C.A., Norinder, U., Hoogstraate, J., and Artursson, P. 2008. Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2). J. Med. Chem. 51:3275-3287.
41. Rius, M., Hummel-Eisenbeiss, J., Hofmann, A.F., and Keppler, D. 2005. Substrate specificity of human ABCC4 (MRP4)-mediated cotransport of bile acids and reduced glutathione. Am. J. Physiol. Gastrointest. Liver Physiol. 290:640-649.
42. Rolo, A.P., Palmeira, C.M., Holy, J.M., and Wallace, K.B. 2004. Role of mitochondrial dysfunction in combined bile acid-induced cytotoxicity: The switch between apoptosis and necrosis. Toxicol. Sci. 79:196-204.
43. Russel, F.G., Koenderink, J.B., and Masereeuw, R. 2008. Multidrug resistance protein 4 (MRP4/ABCC4): A versatile efflux transporter for drugs and signalling molecules. Trends Pharmacol. Sci. 29:200-207.
44. Saito, H., Osumi, M., Hirano, H., Shin, W., Nakamura, R., and Ishikawa, T. 2009. Technical pitfalls and improvements for high-speed screening and QSAR analysis to predict inhibitors of the human bile salt export pump (ABCB11/BSEP). AAPS J. 11:581-589.
45. Sakurai, A., Kurata, A., Onishi, Y., Hirano, H., and Ishikawa, T. 2007. Prediction of drug-induced intrahepatic cholestasis: In vitro screening and QSAR analysis of drugs inhibiting the human bile salt export pump. Expert Opin. Drug Saf. 6:71-86.
46. Snow, K.L. and Moseley, R.H. 2007. Effect of thiazolidinediones on bile acid transport in rat liver. Life Sci. 80:732-740.
47. Stepan, A.F.,Walker, D.P., Bauman, J., Price, D.A., Baillie, T.A., Kalgutkar, A.S., and Aleo, M.D. 2011. Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States. Chem. Res. Toxicol. 24:1345-1410.
48. Stieger, B. 2009. Recent insights into the function and regulation of the bile salt export pump (ABCB11), Current Opinions in Lipidology 20:176-181.
49. Stieger, B. 2010. Role of the bile salt export pump, BSEP, in acquired forms of cholestasis. Drug Metab. Rev. 42:437-445.
50. Stieger, B.,Meier, Y., andMeier, P.J. 2007. The bile salt export pump. Pflugers Arch. 453:611-620.
51. Stine, J.G. and Lewis, J.H. 2011. Drug-induced liver injury: A summary of recent advances. Expert Opin. Drug Metab. Toxicol. 7:875-890.
52. St-Pierre, M.V., Kullak-Ublick, G.A., Hagenbuch, B., and Meier, P.J. 2001. Transport of bile acids in hepatic and non-hepatic tissues. J. Exp. Biol. 204:1673-1686.
53. Trauner, M. and Boyer, J.L. 2003. Bile salt transporters: molecular characterization, function, and regulation. Physiol. Rev. 83:633-671.
54. Xia, C.Q.,Milton, M.N., and Gan, L.S. 2007. Evaluation of drug-transporter interactions using in vitro and in vivo models. Curr. Drug Metab. 8:341-363.
55. Yoshikado, T., Takada, T., Yamamoto, T., Yamaji, H., Ito, K., Santa, T., Yokota, H., Yatomi, Y., Yoshida, H., Goto, J., Tsuji, S., and Suzuki, H. 2011. Itraconazole-induced cholestasis: Involvement of the inhibition of bile canalicular phospholipid translocator MDR3/ABCB4. Mol. Pharmacol. 79:241-250.
56. Zamek-Gliszczynski, M.J., Nezasa, K., Tian, X., Bridges, A.S., Lee, K., Belinsky, M.G., Kruh, G.D., and Brouwer, K.L. 2006. Evaluation of the role of multidrug resistance-associated protein (Mrp) 3 andMrp4 in hepatic basolateral excretion of sulfate and glucuronide metabolites of acetaminophen, 4-methylumbelliferone, and harmol in Abcc3-/-and Abcc4-/-mice. J. Pharmacol. Exp. Ther. 319:1485-1491.
57. Zelcer, N., Huisman, M.T., Reid, G., Wielinga, P., Breedveld, P., Kuil, A., Knipscheer, P., Schellens, J.H., Schinkel, A.H., and Borst, P. 2003. Evidence for two interacting ligand binding sites in human multidrug resistance protein 2 (ATP binding cassette C2). J. Biol. Chem. 278:23538-23544.
58. Zelcer, N., van de Wetering, K., de Waart, R., Scheffer, G.L., Marschall, H.U.,Wielinga, P.R., Kuil, A., Kunne, C., Smith, A., van der Valk, M., Wijnholds, J., Elferink, R.O., and Borst, P. 2006. Mice lacking Mrp3 (Abcc3) have normal bile salt transport, but altered hepatic transport of endogenous glucuronides. J. Hepatol. 44:768-775.
59. Zollner, G. and Trauner, M. 2008. Mechanisms of cholestasis. Clin. Liver Dis. 12:1-26. Z
60. Zollner, G.,Wagner, M., and Trauner, M. 2010. Nuclear receptors as drug targets in cholestasis and drug-induced hepatotoxicity. Pharmacol. Ther. 126:228-243.